Next, the GLP-1 analog liraglutide, an agent approved for the treatment of patients with type 2 diabetes, alleviated MCT-induced PH and suppressed MCT-induced inflammation and EndoMT in pulmonary arteries. This evidence concerns the gene GCG and type 2 diabetes mellitus.